BIO-106 not checked

BiOneCure Therapeutics Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)”In the company’s words, NCT05320588 on ClinicalTrials.gov
Tested for
Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
Main trialPhase 1/2
“A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.”In the company’s words, NCT05320588 on ClinicalTrials.gov

Other drugs for Advanced Cancer

All 2440 drugs for Advanced Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Apr 2024 A Study in Patients With Advanced Cancers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow BIO-106

Following is part of Solo: you see every change to BIO-106 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in